RecruitingPhase 2NCT04515836

Olaparib in Patients With HRD Malignant Mesothelioma

Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma

Sponsor

University of Chicago

Enrollment

56 participants

Start Date

Feb 19, 2021

Study Type

INTERVENTIONAL

Conditions

Homologous Recombination Deficiency Mesothelioma

Summary

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing olaparib (a targeted cancer drug that blocks DNA repair in cancer cells) in people with malignant mesothelioma — a rare cancer typically linked to asbestos exposure — whose tumors have specific DNA repair defects. **You may be eligible if...** - You have been diagnosed with malignant mesothelioma confirmed by a doctor - Your tumor has been tested and shows a specific DNA repair defect (homologous recombination deficiency or HRD) - You have received prior treatment for mesothelioma - You are well enough to participate and can consent on your own **You may NOT be eligible if...** - Your tumor does not have the specific DNA repair defect - You have serious health conditions that would make the study drug unsafe - You are currently pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.